Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neurofibromatosis 1 4Melanoma 4Pancreatic Neoplasms 3Neurofibroma, Plexiform 3Colorectal Neoplasms 3Carcinoma, Hepatocellular 3Rectal Neoplasms 2Colonic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Bile Duct Neoplasms 2Adult Solid Neoplasm 2Uveal Melanoma 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Thymoma 1Small Cell Lung Carcinoma 1Sarcoma 1Peripheral Nervous System Diseases 1Pain 1Neuroblastoma 1Neoplasms, Nerve Tissue 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lung Neoplasms 1Leukemia, Promyelocytic, Acute 1Leukemia, Myeloid, Acute 1Heredodegenerative Disorders, Nervous System 1

Interventions

Specimen Handling 5Oxaliplatin 5Leucovorin 5Magnetic Resonance Spectroscopy 4Fluorouracil 4Erlotinib Hydrochloride 4Biopsy 4Trastuzumab 3Capecitabine 3dehydroftorafur 2cobimetinib 2atezolizumab 2Sorafenib 2N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine 2MK 2206 2Lapatinib 2Interleukin-12 Subunit p35 2Gemcitabine 2Chemotherapy, Adjuvant 2varlilumab 1trametinib 1tipifarnib 1sargramostim 1peposertib 1pembrolizumab 1motexafin lutetium 1ixabepilone 1entinostat 1cediranib 1binimetinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Gallbladder Neoplasms × AZD 6244 × Clear all
NCT01859182 2014-09-09

Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery

National Cancer Institute (NCI)

Phase 2 Withdrawn
Gastrointestinal

Bile Duct Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡